177Lu-PSMA-I&T
- Generic Name
- 177Lu-PSMA-I&T
CONV01-α Combination Therapy Shows 29.8-Month Survival in Advanced Prostate Cancer Trial
• Phase I trial results demonstrate CONV01-α combined with 177Lu-PSMA-I&T achieved 29.8-month median overall survival in metastatic castration-resistant prostate cancer patients, doubling VISION trial outcomes.
• The combination therapy showed impressive efficacy with 94% of patients experiencing PSA decline, while 64% achieved PSA50 response and 80% of evaluable patients converted to favorable circulating tumor cell counts.
• Convergent Therapeutics advances to Phase II CONVERGE-01 trial, evaluating CONV01-α monotherapy in PSMA-positive castration-resistant prostate cancer patients.
177Lu-PSMA-I&T Meets Primary Endpoint in Phase 3 ECLIPSE Trial for mCRPC
• The Phase 3 ECLIPSE trial of 177Lu-PSMA-I&T met its primary endpoint, demonstrating a statistically significant improvement in radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
• 177Lu-PSMA-I&T, a radioligand therapy targeting PSMA, was administered at a dose of 200 mCi every six weeks for up to six doses in the trial.
• The ECLIPSE trial compared 177Lu-PSMA-I&T to hormone therapy in mCRPC patients before taxane-based chemotherapy.
• Curium plans to work with the FDA on a regulatory submission for 177Lu-PSMA-I&T, aiming to provide a new treatment option for mCRPC patients.
Advances in Metastatic Prostate Cancer: Novel Treatment Strategies Emerge
• The ARANOTE trial demonstrated that darolutamide plus ADT significantly improves radiographic progression-free survival in mHSPC patients.
• PEACE-3 trial results highlighted that combining radium-223 with enzalutamide significantly improved outcomes in mCRPC patients with bone metastases.
• SPLASH trial data suggests 177Lu-PNT2002 may offer a new radioligand therapy option for mCRPC patients who have progressed after an ARPI.
Curium and PDRadiopharma Collaborate to Advance PSMA-Targeting Theranostics in Japan
• Curium and PDRadiopharma are partnering to advance clinical development and commercialization of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T theranostics in Japan.
• 177Lu-PSMA-I&T is currently in Phase 3 ECLIPSE trial for metastatic castration-resistant prostate cancer (mCRPC), comparing it to standard hormone therapy.
• 64Cu-PSMA-I&T is being evaluated in Phase 3 SOLAR RECUR and SOLAR STAGE trials for recurrent and newly diagnosed prostate cancer, respectively.
• The collaboration aims to accelerate the availability of these targeted radiopharmaceuticals for prostate cancer diagnosis and treatment in Japan.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath